^
    Back
    Association details:
    Biomarker:ROS1 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:VEGFR-2 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Sci
    Title:

    VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers

    Published date:
    01/07/2021
    Excerpt:
    The combination of VEGFR2 blockade with molecular targeted agents enhanced the anti-tumor effects of these agents in xenograft mouse models of EGFR-, ALK-, or ROS1-altered NSCLC. 
    DOI:
    10.1111/cas.14801